We are live on ! Find out more
NIP

Nicholas Investment Partners Portfolio holdings

AUM $1.78B
1-Year Est. Return 114.03%
This Fund
S&P 500
This Quarter Est. Return
+30%
1 Year Est. Return
+114.03%
3 Year Est. Return
+397.19%
5 Year Est. Return
+640.97%
10 Year Est. Return
+4,729.95%
AUM
$1.29B
AUM Growth
+$370M
Cap. Flow
+$32.1M
Cap. Flow %
2.48%
Top 10 Hldgs %
19.69%
Holding
198
New
29
Increased
74
Reduced
24
Closed
25

Top Buys

Rank Stock Value
1
ARNA
Arena Pharmaceuticals Inc
ARNA
+$20.7M
2
AVTR icon
Avantor
AVTR
+$14.9M
3
TGTX icon
TG Therapeutics
TGTX
+$13.5M
4
CELL
PhenomeX Inc. Common Stock
CELL
+$11.4M
5
TXG icon
10x Genomics
TXG
+$10.3M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$20.9M
2
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$17.8M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$10.4M
4
PEN icon
Penumbra
PEN
+$10.1M
5
TWST icon
Twist Bioscience
TWST
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 48.89%
2 Technology 12.16%
3 Miscellaneous 10.27%
4 Consumer Discretionary 8.78%
5 Industrials 6.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TGTX icon
1
TG Therapeutics
TGTX
$8.64B
$32.7M 2.52%
628,172
+398,720
+174% +$13.5M
BBIO icon
2
BridgeBio Pharma
BBIO
$13.2B
$29.3M 2.26%
411,771
+118,789
+41% +$5.73M
TWST icon
3
Twist Bioscience
TWST
$10.3B
$25.3M 1.95%
178,875
-90,645
-34% -$10.1M
TDOC icon
4
Teladoc Health
TDOC
$1.14B
$25.2M 1.95%
126,104
+32,704
+35% +$6.65M
RGEN icon
5
Repligen
RGEN
$10.1B
$25M 1.93%
130,491
+290
+0.2% +$52.8K
ARGX icon
6
argenx
ARGX
$62.3B
$24.5M 1.89%
83,328
-77
-0.1% -$21.2K
IOVA icon
7
Iovance Biotherapeutics
IOVA
$4.54B
$23.6M 1.82%
507,651
+837
+0.2% +$33.2K
NVCR icon
8
NovoCure
NVCR
$1.95B
$23.4M 1.81%
135,336
-64,277
-32% -$8.8M
BHVN
9
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$23.2M 1.79%
270,362
+18,416
+7% +$1.56M
KRNT icon
10
Kornit Digital
KRNT
$661M
$22.8M 1.76%
256,334
-13,820
-5% -$1.06M
NEO icon
11
NeoGenomics
NEO
$2.56B
$22.7M 1.75%
420,807
+717
+0.2% +$32.4K
TPTX
12
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$22.4M 1.73%
183,676
+319
+0.2% +$34.9K
CZR icon
13
Caesars Entertainment
CZR
$6.05B
$22M 1.7%
295,852
+3,408
+1% +$214K
ARNA
14
DELISTED
Arena Pharmaceuticals Inc
ARNA
$21.3M 1.64%
+276,633
New +$20.7M
HZNP
15
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$20.9M 1.61%
285,046
+20,690
+8% +$1.54M
MPWR icon
16
Monolithic Power Systems
MPWR
$57.5B
$20.3M 1.57%
55,526
+247
+0.4% +$79.2K
EXAS
17
DELISTED
Exact Sciences
EXAS
$20.1M 1.55%
151,746
+234
+0.2% +$28.3K
INSP icon
18
Inspire Medical Systems
INSP
$2.1B
$19.8M 1.53%
105,095
-1,018
-1% -$166K
SDGR icon
19
Schrodinger
SDGR
$2.26B
$19.7M 1.52%
248,806
+12,983
+6% +$816K
GH icon
20
Guardant Health
GH
$24.6B
$19.6M 1.51%
152,048
+13,948
+10% +$1.6M
OSH
21
DELISTED
Oak Street Health, Inc.
OSH
$18.6M 1.43%
303,407
+46,492
+18% +$2.44M
LSCC icon
22
Lattice Semiconductor
LSCC
$15.4B
$18M 1.39%
392,706
-42,729
-10% -$1.65M
AXSM icon
23
Axsome Therapeutics
AXSM
$11.2B
$16.9M 1.31%
207,452
+19,696
+10% +$1.47M
AVTR icon
24
Avantor
AVTR
$10.7B
$16.3M 1.26%
+579,037
New +$14.9M
CELL
25
DELISTED
PhenomeX Inc. Common Stock
CELL
$15.9M 1.23%
177,724
+135,440
+320% +$11.4M
1
2 3 4 5

Similar funds

FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.77B AUM 34.52% 1-Year Est. Return
CC
Covalis Capital London, United Kingdom $1.77B AUM 26.68% 1-Year Est. Return
WC
Waterloo Capital Austin, Texas $1.78B AUM 27.25% 1-Year Est. Return
IP
Indivisible Partners Clearwater, Florida $1.77B AUM
BCIM
Black Creek Investment Management Toronto, Ontario, Canada $1.78B AUM 5.83% 1-Year Est. Return
SGAM
Stephens Group Asset Management Little Rock, Arkansas $1.77B AUM 17.59% 1-Year Est. Return
GWANC
Guardian Wealth Advisors (North Carolina) Raleigh, North Carolina $1.78B AUM 19.66% 1-Year Est. Return
CIA
Capital Impact Advisors Boston, Massachusetts $1.78B AUM 56.11% 1-Year Est. Return

Nicholas Investment Partners's Q4 2020 Portfolio in Review

As of Q4 2020, Nicholas Investment Partners held 198 positions worth $1.29B, up 40% from $925M the previous quarter. Its ten largest holdings account for 20% of the portfolio.

Nicholas Investment Partners's Q4 2020 filing shows 29 new, 74 increased, 24 reduced and 25 closed positions. Its largest new stake was Arena Pharmaceuticals Inc: 276,633 shares worth $21.3M. The largest sale was Immunomedics Inc, an estimated $20.9M.

By sector, the portfolio is most concentrated in Healthcare at 49% of assets, down from 52% a quarter earlier, followed by Technology and Miscellaneous.

  • Nicholas Investment Partners's largest Q4 2020 buy was Arena Pharmaceuticals Inc: 276,633 shares worth $21.3M.
  • Nicholas Investment Partners added most to TG Therapeutics in Q4 2020, an estimated $13.5M increase.
  • Nicholas Investment Partners's biggest Q4 2020 reduction was Twist Bioscience, cutting an estimated $10.1M.
  • Nicholas Investment Partners fully exited Immunomedics Inc in Q4 2020, selling an estimated $20.9M.
  • Nicholas Investment Partners's ten largest holdings make up 20% of its $1.29B portfolio in Q4 2020.
  • Nicholas Investment Partners opened 29 new positions and closed 25 in Q4 2020.
  • Nicholas Investment Partners's portfolio value rose 40% quarter-over-quarter to $1.29B.

Based on Nicholas Investment Partners's 13F filing for Q4 2020, filed 11 Feb 2021.